Everolimus + lanreotide vs everolimus for unresectable GEP neuroendocrine tumor #ASCOGI25
🔎JCOG1901, STARTER-NET phs-3
👉ORR 8.7 vs 23%, DCR: 87 vs 91.5%
👉mPFS 11.5 vs 29.7 mo
👉no OS benefit
🧐 EVE/LAN valid option for GEP-NETs with poor prognostic factors
@myESMO
#ASCOGI25